David Pring-Mill

Staloral Birch Phase III Study Reports Positive Results in Pediatric Allergy Treatment

Biotech/Pharma /

Allergic rhinoconjunctivitis affects more than 500 million people worldwide, with children facing particular challenges including sleep disruption, missed school days, and increased asthma risk. Stallergenes Greer announced that its Phase IIIb clinical study for Staloral Birch, a sublingual allergen immunotherapy, […]

Staloral Birch Phase III Study Reports Positive Results in Pediatric Allergy Treatment Read More »

Green Nanotechnology Shows Promise for Sustainable Implantable Biosensors in Medical Applications

Innovation /

Toxic chemicals used to manufacture implantable biosensors may soon be replaced by plant extracts and bacteria. Researchers at IUBAT-International University of Business Agriculture and Technology published a comprehensive literature review examining how “green” nanotechnology could transform biosensor production, reducing environmental

Green Nanotechnology Shows Promise for Sustainable Implantable Biosensors in Medical Applications Read More »

Pharmaron Acquires Biortus to Expand Structural Biology Capabilities

Biotech/Pharma, M&A /

As pharmaceutical R&D services increasingly rely on structural biology and AI-driven platforms, contract research organizations are consolidating capabilities to offer more integrated solutions. Pharmaron Beijing Co., Limited has entered into an agreement to acquire 82.54% equity interest in Biortus Biosciences

Pharmaron Acquires Biortus to Expand Structural Biology Capabilities Read More »

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trial of ENHERTU in First-Line HER2 Overexpressing Lung Cancer

Biotech/Pharma /

Patients with metastatic lung cancer and low PD-L1 expression face limited targeted treatment options in the first-line setting, with current standard care relying on immunotherapy combined with traditional chemotherapy. Daiichi Sankyo and AstraZeneca have initiated the DESTINY-Lung06 phase 3 trial,

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trial of ENHERTU in First-Line HER2 Overexpressing Lung Cancer Read More »

Machine Learning Models Achieve 95% AUC in Predicting Heart Complications

Innovation /

Elderly heart attack patients face complex risk profiles that traditional scoring systems struggle to assess accurately. Researchers at Tehran Heart Center have developed machine learning models that significantly outperform conventional risk stratification tools, potentially enabling more personalized care for this

Machine Learning Models Achieve 95% AUC in Predicting Heart Complications Read More »